The electrochemical reduction of CO2 to value-added products represents a promising strategy to store renewable energy and realize global carbon neutrality. Bi-based materials have attracted extensive attention for formate production...
e21741 Background: The skeletal system is one of the most common distant sites of metastatic non-small cell lung cancer (NSCLC) which may lead to skeletal-related events (SREs). Bone metastasis can reduced quality of life. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone metastasis in animal models. Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), which is inhibits tumor angiogenesis. Therefore, we aimed to investigate the efficacy and safety of apatinib plus docetaxel for NSCLC with bone metastases. Methods: Eligible patients of NSCLC with bone metastases who received first-line platinum-based chemotherapy. Treated with apatinib (500 mg, qd, orally) plus docetaxel (60mg/m2, q3w, iv) and zoledronic acid (4mg, q3w, iv). Treatment was continued until disease progression or unacceptable toxic effects. Results: Between July 2017 and June 2019, 10 patients were enrolled. All patients available for efficacy and safety evaluation. the objective response rate (ORR) was 50% and the disease control rate (DCR) was 80%. The median progression-free survival (PFS) was 6.5 months, The proportions of patients with SREs were 20%. The most common Grade 1 or 2 adverse events included hypertension (30%, 3/10), fatigue (30%, 3/10), digestive tract reaction (30%, 3/10), leukopenia (20%, 2/10). Conclusions: Apatinib plus docetaxel prolonged PFS and reduced the incidence of SREs, with acceptable toxic effects. The therapeutic regime may be an option for NSCLC with bone metastases. Clinical trial information: NCT03127319.
Proton exchange membrane water electrolysers and alkaline exchange membrane water electrolysers for hydrogen production suffer from sluggish kinetics and the limited durability of the electrocatalyst toward oxygen evolution reaction (OER). Herein, a rutile Ru0.75Mn0.25O2−δ solid solution oxide featured with a hierarchical porous structure has been developed as an efficient OER electrocatalyst in both acidic and alkaline electrolyte. Specifically, compared with commercial RuO2, the catalyst displays a superior reaction kinetics with small Tafel slope of 54.6 mV dec−1 in 0.5 M H2SO4, thus allowing a low overpotential of 237 and 327 mV to achieve the current density of 10 and 100 mA cm−2, respectively, which is attributed to the enhanced electrochemically active surface area from the porous structure and the increased intrinsic activity owing to the regulated Ru>4+ proportion with Mn incorporation. Additionally, the sacrificial dissolution of Mn relieves the leaching of active Ru species, leading to the extended OER durability. Besides, the Ru0.75Mn0.25O2−δ catalyst also shows a highly improved OER performance in alkaline electrolyte, rendering it a versatile catalyst for water splitting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.